Hemoglobinuria of Marchiafava-Micheli

Clinical Guide: Hemoglobinuria of Marchiafava-Micheli (Paroxysmal Nocturnal Hemoglobinuria)

1. Comprehensive Introduction & Overview

Hemoglobinuria of Marchiafava-Micheli, clinically recognized in modern nomenclature as Paroxysmal Nocturnal Hemoglobinuria (PNH), is a rare, acquired, life-threatening hematopoietic stem cell disorder. Historically identified by the Italian physicians Ettore Marchiafava and Ferdinando Micheli in the early 20th century, the condition is characterized by the chronic destruction of red blood cells (hemolysis), blood clot formation (thrombosis), and impaired bone marrow function.

PNH is uniquely classified as a clonal disorder arising from a somatic mutation in the PIGA gene within a hematopoietic stem cell. This mutation prevents the synthesis of the glycosylphosphatidylinositol (GPI) anchor, a protein structure required to tether various protective proteins to the cell surface. Without these anchors, blood cells lack the "shield" necessary to protect themselves from the host’s own complement system, leading to uninhibited complement-mediated cell lysis.

2. Technical Specifications & Pathophysiology

The Molecular Defect

The PIGA gene (Phosphatidylinositol Glycan Anchor Biosynthesis Class A) is located on the X chromosome. Because hematopoietic stem cells are clonal, a single mutation results in a population of progeny cells that are all deficient in GPI-anchored proteins (GPI-APs).

Key Missing Proteins

The lack of GPI-APs results in the absence of two critical complement-regulatory proteins:
* CD55 (Decay-Accelerating Factor): Prevents the formation of C3 convertases.
* CD59 (Membrane Inhibitor of Reactive Lysis): Prevents the assembly of the Membrane Attack Complex (MAC/C5b-9).

Pathophysiological Cascade

1. Intravascular Hemolysis: The absence of CD59 allows the MAC to puncture the erythrocyte membrane, causing hemoglobin release into the plasma (hemoglobinemia) and subsequent excretion in urine (hemoglobinuria).
2. Nitric Oxide (NO) Scavenging: Free hemoglobin released during hemolysis binds avidly to nitric oxide. This depletion of NO leads to smooth muscle dystonia, resulting in esophageal spasms, erectile dysfunction, and abdominal pain.
3. Prothrombotic State: The loss of protective proteins on platelets and the release of pro-coagulant factors from lysed RBCs create a hypercoagulable environment, significantly increasing the risk of venous thromboembolism (VTE).

3. Clinical Indications & Standard Presentation

PNH is a multisystemic disease. While "paroxysmal" (intermittent) and "nocturnal" (worse at night) were the classic descriptors, modern clinical practice recognizes that hemolysis is usually chronic and continuous, though it may be exacerbated by infections or physiological stress.

Clinical Triad

• Hemolytic Anemia: Fatigue, pallor, dyspnea, and jaundice.
• Thrombosis: The leading cause of mortality in PNH patients. Occurs in atypical sites (e.g., Budd-Chiari syndrome, cerebral veins, mesenteric veins).
• Pancytopenia: Bone marrow failure often co-exists with PNH due to the underlying stem cell dysfunction.

Diagnostic Staging

There is no formal "staging" system like cancer, but clinicians utilize the PNH Clone Size to assess risk:
* Small Clone (<10%): Often clinically silent; requires monitoring.
* Intermediate Clone (10–50%): Risk of hemolysis and thrombotic events increases significantly.
* Large Clone (>50%): High risk of severe hemolytic crisis and overt thrombosis.

4. Differential Diagnosis

Distinguishing PNH from other hemolytic anemias is critical for therapeutic selection.

5. Key Diagnostic Tests

Modern diagnostics have moved away from the historic "Ham’s Test" (acidified serum lysis) toward high-sensitivity flow cytometry.

1. High-Sensitivity Flow Cytometry (Gold Standard): Analyzes peripheral blood for the absence of GPI-anchored proteins (CD55, CD59) on granulocytes and erythrocytes.
2. Complete Blood Count (CBC): Typically reveals anemia, leukopenia, and thrombocytopenia.
3. Lactate Dehydrogenase (LDH): A primary biomarker of intravascular hemolysis. Elevated levels correlate directly with disease activity.
4. Haptoglobin: Levels are typically undetectable due to saturation by free hemoglobin.
5. Bone Marrow Aspiration/Biopsy: Performed to rule out underlying myelodysplastic syndrome or aplastic anemia.

6. Risks, Side Effects, and Therapeutic Contraindications

The management of PNH has been revolutionized by complement inhibitors.

Standard Therapies

• C5 Inhibitors (Eculizumab/Ravulizumab): These monoclonal antibodies bind to C5 and prevent the formation of the membrane attack complex.
  • Major Risk: Increased susceptibility to Neisseria meningitidis infection.
  • Mandatory Requirement: Meningococcal vaccination (serogroups A, C, W, Y, and B) must be administered at least two weeks prior to the first dose. Prophylactic antibiotics are often recommended.
• Factor D Inhibitors (Pegcetacoplan): A proximal complement inhibitor that acts at the level of C3. It is highly effective but may lead to extravascular hemolysis in some patients.

Contraindications

• Splenectomy: Generally discouraged in PNH due to the already heightened risk of thrombosis.
• Iron Supplementation: Must be used cautiously. While patients are often iron deficient due to urinary loss, aggressive replacement can stimulate the bone marrow to produce more PNH-clones, potentially worsening hemolysis.

7. Long-term Prognosis

With the advent of targeted C5 inhibition, the life expectancy of PNH patients has improved significantly, approaching that of the general population. However, patients remain at risk for:
* Malignant Transformation: Progression to Acute Myeloid Leukemia (AML) occurs in a small percentage of patients.
* Chronic Kidney Disease (CKD): Long-term deposition of hemosiderin in renal tubules leads to progressive renal failure.
* Thrombotic Events: Even with treatment, vigilance is required for signs of DVT or PE.

8. Massive FAQ Section

1. Is PNH a form of cancer?
PNH is a clonal hematopoietic stem cell disorder. While it is not a "cancer" in the traditional sense, it is a precursor state that can progress to bone marrow failure or leukemia.

2. Why is the urine dark in PNH patients?
The dark, tea-colored urine is due to the presence of free hemoglobin (hemoglobinuria) resulting from the rupture of red blood cells within the blood vessels.

3. Does PNH run in families?
No. PNH is caused by a somatic mutation in the PIGA gene, meaning it is acquired during a person's lifetime and is not inherited from parents.

4. How often should LDH levels be monitored?
In stable patients, monitoring every 3 to 6 months is standard. During active hemolysis or dose adjustments of medication, monitoring should be more frequent.

5. What is the biggest danger for a PNH patient?
Thrombosis (blood clots) is the leading cause of mortality. Clots can occur in unusual areas like the abdomen or the brain.

6. Can PNH be cured?
Currently, the only curative treatment is an allogeneic hematopoietic stem cell transplant. However, because of the risks associated with transplant, it is usually reserved for patients with severe bone marrow failure.

7. Why do I need a meningitis vaccine if I take Eculizumab?
Eculizumab blocks the body's natural defense against Neisseria meningitidis. Without the vaccine, patients are at a significantly higher risk of life-threatening meningococcal infection.

8. Is pregnancy possible with PNH?
Yes, but it is considered high-risk. Pregnancy increases the risk of thrombosis and worsening hemolysis. Management requires a multidisciplinary team of hematologists and obstetricians.

9. Can I take iron supplements for my anemia?
Only under strict medical supervision. Because iron fuels the production of blood cells, it may ironically increase the number of PNH-affected cells and intensify hemolysis.

10. What is the difference between Eculizumab and Ravulizumab?
Both are C5 inhibitors. Ravulizumab is a long-acting version, which allows for dosing every 8 weeks, whereas Eculizumab requires dosing every 2 weeks.

Summary Checklist for Clinical Management

• [ ] Baseline Screening: Flow cytometry for CD55/CD59 expression.
• [ ] Vaccination: Ensure meningococcal vaccine series is complete.
• [ ] Baseline Imaging: Doppler ultrasound to rule out asymptomatic venous thrombosis.
• [ ] Monitoring: Serial LDH, haptoglobin, and CBC; annual renal function testing.
• [ ] Patient Education: Instruct patient to seek immediate care for sudden abdominal pain, headache, or dark urine.

Disclaimer: This guide is intended for medical education and professional reference. Clinical decisions must always be guided by current patient data and institutional protocols.